Evidence map›Paper›PMID 38785826›Full record

ArticleBiology2024

Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.

Naoko Nakatani, Kaung Htet Nay Win, Cho Yee Mon, Tomoko Fujikawa, Suguru Uemura, Atsuro Saito, Toshiaki Ishida, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka and 7 more

Abstract read
In one paragraph

Article in Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Naoko NakataniDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Kaung Htet Nay WinDepartment of Public Health, Kobe University Graduate School of Health Science, Kobe 654-0142, Japan.ORCID 0000-0002-4178-1398
Cho Yee MonDepartment of Public Health, Kobe University Graduate School of Health Science, Kobe 654-0142, Japan.ORCID 0000-0002-7492-9678
Tomoko FujikawaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Suguru UemuraDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.
Atsuro SaitoDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.
Toshiaki IshidaDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.ORCID 0000-0002-8327-1089
Takeshi MoriDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.ORCID 0000-0003-0029-7265
Daiichiro HasegawaDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.
Yoshiyuki KosakaDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.
Shotaro InoueDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Akihiro NishimuraDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Nanako NinoDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe 650-0047, Japan.
Akihiro TamuraDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Nobuyuki YamamotoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.ORCID 0000-0002-1006-7394
Kandai NozuDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.ORCID 0000-0002-0290-3137
Noriyuki NishimuraDepartment of Public Health, Kobe University Graduate School of Health Science, Kobe 654-0142, Japan.ORCID 0000-0002-9000-4341

Funding

Japan Society for the Promotion of Science 21K07750Japan Society for the Promotion of Science 23K14977
6 · The paper itself

Abstract

Non-high-risk (non-HR) neuroblastoma (NB) patients have excellent outcomes, with more than a 90% survival rate, whereas HR NB patients expect less than a 50% survival rate. Metastatic disease is the principal cause of death among both non-HR and HR NB patients. Previous studies have reported the significant but limited prognostic value of quantitative PCR (qPCR)-based assays, measuring overlapping but different sets of neuroblastoma-associated mRNAs (NB-mRNAs), to detect metastatic disease in both non-HR and HR patient samples. A droplet digital PCR (ddPCR)-based assay measuring seven NB-mRNAs (CRMP1, DBH, DDC, GAP43, ISL1, PHOX2B, and TH mRNAs) was recently developed and exhibited a better prognostic value for HR patient samples than qPCR-based assays. However, it remained to be tested on non-HR patient samples. In the present study, we employed the ddPCR-based assay to study peripheral blood (PB) and bone marrow (BM) samples collected at diagnosis from eight non-HR and eleven HR cases and characterized the expression profiles of NB-mRNAs. The most highly expressed NB-mRNAs in PB and BM differed between non-HR and HR cases, with the CRMP1 mRNA being predominant in non-HR cases and the GAP43 mRNA in HR cases. The levels of NB-mRNAs in PB and BM were 5 to 1000 times lower in non-HR cases than in HR cases. The PB to BM ratio of NB-mRNAs was 10 to 100 times higher in non-HR cases compared to HR cases. The present case series suggests that non-HR and HR NB patients have the distinct expression profiles of NB-mRNAs in their PB and BM.

Indexed as

bone marrow (BM)high-risk (HR) neuroblastoma (NB)neuroblastoma-associated mRNAs (NB-mRNAs)non-high-risk (non-HR) neuroblastoma (NB)peripheral blood (PB)

Identifiers

PMID38785826
PMCPMC11117621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.